[18F]CTT1057 PET以组织病理学为标准检测PSMA阳性肿瘤的影像效能:GuideView 2/3期前瞻性多中心研究结果
GuideView前瞻性多中心研究纳入计划行根治性前列腺切除术的新诊断未治疗高危前列腺癌患者,评估[18F]CTT1057 PET/CT以组织病理学为标准检测PSMA阳性病灶的影像效能。184例接受中位355 MBq药物,172例可评估疗效,患者水平敏感度和区域水平特异度均达到预设成功标准,药物安全性良好。
要点
- 患者水平敏感度范围为86.8%-90.0%,95%CI下限为80.7%-84.5%,超过50%的成功标准。
- 区域水平特异度为97.1%,95%CI下限为92.7%,超过70%的成功标准。
- 读者间Fleiss κ为63.9%,读者内Cohen κ为89.4%-100%。
核心结论
- GuideView研究证实[18F]CTT1057检测PSMA阳性病灶具有高患者水平敏感度和区域水平特异度。
- 读者间存在较大变异性而读者内重复性几乎完美,提示[18F]CTT1057结果稳健可靠。
- 作者认为[18F]CTT1057将有助于扩大PSMA PET影像的可及性,以恰当诊断和治疗前列腺癌患者。
研究设计与样本
- 前瞻性多中心研究(GuideView,NCT04838626)。
- 2021年9月7日至2023年10月26日筛查201例计划行根治性前列腺切除术的患者,入组195例。
- 184例接受中位355 MBq(范围195-400 MBq)[18F]CTT1057,90分钟(±30分钟)后行PET/CT。
- 3名设盲的中心独立读者评估图像,以组织病理学为标准真相。
- 共同主要终点为患者水平敏感度(含原发肿瘤和盆腔淋巴结)和区域水平特异度(仅含盆腔淋巴结)。
主要发现
- 184例接受药物者中172例可评估疗效,每例患者中位清扫19枚淋巴结(四分位距13.0-28.5枚)。
- 3名读者患者水平敏感度范围为86.8%-90.0%,95%CI下限为80.7%-84.5%。
- 区域水平特异度为97.1%,95%CI下限为92.7%。
- 读者间变异性Fleiss κ为63.9%,读者内重复性Cohen κ为89.4%-100%。
- [18F]CTT1057安全性特征良好。
关键数值与推荐
- 共同主要终点成功标准:患者水平敏感度95%CI下限需超过50%,区域水平特异度95%CI下限需超过70%。
- 成功定义为3名中心读者中至少2名达到上述标准,本研究3名读者在两个终点上均达到成功标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
[18F]CTT1057 is a highly selective prostate-specific membrane antigen (PSMA)-targeted PET radiotracer for prostate cancer (PCa) detection. This prospective study (GuideView, NCT04838626) evaluates the imaging efficacy of [18F]CTT1057 PET to detect PSMA-positive lesions against histopathology in patients with newly diagnosed, untreated, high-risk PCa. Methods: Between September 7, 2021, and October 26, 2023, 201 patients planned for radical prostatectomy were screened and 195 patients were enrolled. Of these, 184 patients received a median of 355 MBq (range, 195-400 MBq) of [18F]CTT1057 and underwent PET/CT 90 min (±30 min) later. Three masked central independent readers evaluated the images. Coprimary endpoints were patient-level sensitivity (including primary tumor and pelvic lymph nodes) and region-level specificity (including pelvic lymph nodes only) for detection of PSMA-positive lesions, using histopathology as the standard of truth. The lower-bound 95% CI needed to surpass 50% for patient-level sensitivity and 70% for region-level specificity. Success was defined as at least 2 of 3 central readers meeting these criteria. Secondary endpoints included the patient-level and region-level positive predictive value and accuracy, region-level sensitivity, inter- and intrareader variability, detection rate of distant metastasis, pharmacokinetics, and safety and tolerability assessments. Results: Of the 184 patients who received [18F]CTT1057, 172 patients were evaluable for efficacy. Among these, a median of 19 lymph nodes (interquartile range, 13.0-28.5 lymph nodes) were dissected per patient. Both coprimary endpoints were met, with lower bounds of 95% CIs surpassing the success criteria for all 3 readers for both patient-level sensitivity (range, 86.8%-90.0%; lower-bound 95% CI, 80.7%-84.5%) and region-level specificity (97.1%; lower-bound 95% CI, 92.7%). Interreader variability Fleiss κ was 63.9%; intrareader reproducibility Cohen κ was 89.4%-100%. [18F]CTT1057 had a favorable safety profile. Conclusion: GuideView confirmed the imaging efficacy of [18F]CTT1057 for the detection of PSMA-positive lesions, with high patient-level sensitivity and region-level specificity. Substantial interreader variability and almost perfect intrareader reproducibility suggest that [18F]CTT1057 findings are robust and reliable. [18F]CTT1057 will contribute to expanding access to PSMA PET imaging to properly diagnose and treat patients with PCa.
引用
- Iagaru A, Suarez JF, Behr S, et al. Imaging Efficacy of [18F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study. J Nucl Med. 2025. PMID: 40473463. doi:10.2967/jnumed.124.269007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。